CD274 and lung adenocarcinoma: Therefore, PD-1/PD-L1 inhibitors are expected to be a promising remedy for early-stage lung adenocarcinoma patients and PD-L1 expression is likely to be the best predictive biomarker or one of the best biomarker combinations for predicting efficacy in these patients.